아이겐드럭은 한국제약바이오협회, AI신약개발지원센터의 "현장 중심 협력 교육"에 선정되었다.
이번 과제를 통해 아이겐드럭은 "인공지능을 활용한 자가면역 질환 합성신약 유효물질(Hit) 발굴" 연구를 (주)팜젠사이언스와 함께 수행할 예정이다.

아이겐드럭은 과학기술정보통신부의 "인공지능 활용 혁신신약 발굴 사업"에 최종 선정되었다.

(주)아이겐드럭은 2022년 4월 14일 기업부설 연구소인 "인공지능신약개발 연구소"를 설립하였다.

Dr. Sun Kim was invited to serve on the IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB) Steering Committee as an Association for Computing Machinery (ACM) representative from January 1, 2022.

주주 각위의 건승을 경하드립니다.
당사 정관 제24조의 규정에 의거 다음과 같이 2022년도 제1기 정기주주총회를 개최하오니 참석하여 주시기 바랍니다.

Dr. Sun Kim’s work on deep learning modeling of GPCR protein family hierarchy was selected by Faculty Opinions.

Dr. Sun Kim was awarded prestigious “Ilchun Memorial Lecture” and gave a lecture “Modern AI Technologies: Innovative Toolkits for the Investigation of Fundamental Questions in Molecular Biology” at the international conference, organized by the Korean Society for Molecular and Cellular Biology (KSMCB) 2021.

AIgenDrug started the 'AI ​​platform for drug target' project to provide drug target prediction service.

On August 25, 2021, AIgenDrug signed an MoU with three experts at Seoul National University for the development and deployment of an AI drug toxicity prediction model.

AIgenDrug is proud to announce that Dr. Sunho Lee takes the role of Vice President and Chief Technology Officer (CTO). He will lead the company’s technical strategy and business development for AI drug discovery.